Mechanisms of adaptive resistance to targeted therapy in RET-aberrant cancers

Clin Cancer Res. 2025 Jan 14. doi: 10.1158/1078-0432.CCR-24-3734. Online ahead of print.

Abstract

The success of targeted therapies in oncogene-driven cancer is limited by adaptive or acquired treatment resistance, leading to disease progression. A recent study reports that YAP-dependent HER3 activation constitutes a therapeutic vulnerability of adaptive resistance to RET-targeted therapies in RET-altered cancers, highlighting a promising strategy to improve RET-inhibitor tumor responses.